Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2010
06/15/2010CA2410253C Regulating lipid levels via the zmax1 or hbm gene
06/15/2010CA2393650C Novel 1,8-naphthyridin-2(1h)-one derivatives
06/15/2010CA2379103C Novel spiro compounds
06/15/2010CA2341700C Compositions and methods for treatment of mitochondrial diseases
06/15/2010CA2328922C Terminally-branched polymeric linkers and polymeric conjugates containing the same
06/10/2010WO2010065834A1 Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
06/10/2010WO2010065671A2 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
06/10/2010WO2010065306A1 Treatment of heart tissue via localized delivery of parp inhibitors
06/10/2010WO2010065069A2 Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
06/10/2010WO2010064737A1 Heterocyclic compound and use of the same
06/10/2010WO2010064714A1 Nutrient composition
06/10/2010WO2010064707A1 2h-chromene compound and derivative thereof
06/10/2010WO2010064665A1 Therapeutic agents
06/10/2010WO2010064633A1 Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
06/10/2010WO2010064597A1 Piperidine derivative
06/10/2010WO2010064020A1 Imidazopyridine compounds
06/10/2010WO2010063995A2 Telmisartan with diuretic formulations
06/10/2010WO2010063724A1 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
06/10/2010WO2010063402A1 Substituted benzyl and phenylsulfonyl triazolones, and use thereof
06/10/2010WO2010063237A1 Methods and reagents for the diagnosis, prevention and treatment of insulin resistance
06/10/2010WO2010043976A3 Highly pure ranolazine or a pharmaceutically acceptable salt thereof
06/10/2010WO2010032875A3 Heterocyclic carboxamide compounds
06/10/2010WO2010025370A3 Preparation of ranolazine
06/10/2010WO2010013835A3 Solid pharmaceutical composition
06/10/2010WO2010011349A3 Pyrimidine-2,4-diamines as jak2 kinase inhibitors for treatment of inflammation
06/10/2010WO2010011331A3 Compositions and methods related to sirt1 function
06/10/2010WO2010011319A3 Magnetic heating for drug delivery and other applications
06/10/2010WO2009157018A9 Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof
06/10/2010WO2009149161A3 Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
06/10/2010WO2009147170A3 Drug combinations comprising a dgat inhibitor and a ppar-agonist
06/10/2010WO2009128738A3 Use of the extract of defatted seeds of primrose
06/10/2010WO2009115658A3 Use of a caspase-1 inhibitor for treating atherosclerotic plaque
06/10/2010WO2009073186A8 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
06/10/2010WO2009033561A8 Substituted 6-phenylnicotinic acids and the use thereof
06/10/2010US20100145441 Therapeutic agents for angiogenesis-related diseases comprising chondromodulin-i as active ingredient
06/10/2010US20100145180 Apparatus for physical measurements of the eye
06/10/2010US20100144886 Method for treating pulmonary arterial hypertension
06/10/2010US20100144873 Treatment of myocarditis using fts
06/10/2010US20100144868 Novel Neuroprotective Compounds and Uses Thereof
06/10/2010US20100144862 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
06/10/2010US20100144853 Novel combined administration
06/10/2010US20100144852 Bicyclo[2.2.1]hept-7-ylamine Derivatives and Their Uses
06/10/2010US20100144835 Inhibition of gpr4
06/10/2010US20100144827 Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
06/10/2010US20100144824 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
06/10/2010US20100144816 Functionally selective alpha2c adrenoreceptor agonists
06/10/2010US20100144810 Angiotensin ii receptor antagonists
06/10/2010US20100144800 extended release tablet formulation of niacin
06/10/2010US20100144791 Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
06/10/2010US20100144789 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity
06/10/2010US20100144782 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
06/10/2010US20100144778 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
06/10/2010US20100144774 Heterocyclic spiro-compounds
06/10/2010US20100144773 Pharmaceutical compositions for intranasal administration comprising choline salts of succinic acid
06/10/2010US20100144768 Kinase inhibitor compounds
06/10/2010US20100144765 5,6-trimethylenepyrimidin-4-one compounds
06/10/2010US20100144764 Pyrimidinedione derivatives and methods of use thereof
06/10/2010US20100144762 Novel sulfonamides as l-cpt1 inhibitors
06/10/2010US20100144760 Novel compounds
06/10/2010US20100144756 Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
06/10/2010US20100144746 Method for restructuring a biological tissue comprising collagen fibrils and relative uses
06/10/2010US20100144744 Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
06/10/2010US20100144736 Novel biphenyl thio-urea derivatives useful as potassium channel modulators
06/10/2010US20100144733 Compounds, compositions and methods comprising heteroaromatic derivatives
06/10/2010US20100144731 Novel Biccyclic Compounds As GATA Modulators
06/10/2010US20100144728 Oxazolidinone For The Treatment And Prophylaxis Of Pulmonary Hypertension
06/10/2010US20100144722 Novel heterocyclic compounds as gata modulators
06/10/2010US20100144721 Inhibitors of c-met and uses thereof
06/10/2010US20100144701 Modulators of CB1 Receptors
06/10/2010US20100144698 Substituted azetidinones
06/10/2010US20100144697 Stabilized pharmaceutical compositions containing a calcium channel blocker
06/10/2010US20100144696 Stabilized pharmaceutical compositions containing a calcium channel blocker
06/10/2010US20100144675 Regulation of sGC Function by Corrin Derivatives
06/10/2010US20100144670 Particle Formation
06/10/2010US20100144665 Treatment of statin side effects
06/10/2010US20100144653 Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
06/10/2010US20100144644 Metal-binding compounds and uses therefor
06/10/2010US20100144635 Methods and compositions to treat myocardial conditions
06/10/2010US20100144632 Administering a polypeptide having at least one of anti-angiogenic, tumor-suppressive, or anti-migratory activity, but does not have stimulation of cell proliferation activity
06/10/2010US20100144624 Process for the preparation of compositions of at1 receptor antagonist and angiotensin-(1-7)
06/10/2010US20100144621 Use of Exendins and Exendin Agonists and GLP-1 Receptor Agonists for Altering the Concentration of Fibrinogen
06/10/2010US20100144616 Neuroprotective methods and reagents
06/10/2010US20100144599 Vegf pathway blockade
06/10/2010US20100144594 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as scd inhibitors
06/10/2010US20100143962 Nanoparticulate polycosanol formulations & novel polycosanol combinations
06/10/2010US20100143513 Composition Comprising Starch Or Dietary Fiber From Gramineae Plant For Prevention And Treatment Of Ischemic Diseases And Degenerative Brain Disease
06/10/2010US20100143470 Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
06/10/2010US20100143465 Pharmaceutical composition
06/10/2010US20100143460 Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
06/10/2010US20100143459 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
06/10/2010US20100143424 Casein nanoparticle
06/10/2010US20100143420 Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
06/10/2010US20100143380 Compositions and methods for macular degeneration
06/10/2010US20100143360 Human vascular endothelial growth factor 2
06/10/2010US20100143349 Humanized anti-rage antibody
06/10/2010US20100143347 Targeting ncca-atp channel for organ protection following ischemic episode
06/10/2010US20100143336 Toll-like receptor binding epitope and compositions for binding thereto
06/10/2010US20100143335 Treating atherosclerosis
06/10/2010US20100143331 Method for mixing powders
06/10/2010US20100143325 Composition And Methods Involving Thrombolytic Agents
1 ... 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 ... 1595